Citations

Showing 10 of 108104 citations.

Editor's evaluation: Precise in vivo functional analysis of DNA variants with base editing using ACEofBASEs target prediction
Ekker, Stephen C.

Mayo Clinic

No container title available | April 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.72124.sa0 Get It

Independent predictors of vertebral compression fracture following radiation for metastatic spine disease
Mikula, Anthony L., Pennington, Zach, Lakomkin, Nikita, Clarke, Michelle J., Rose, Peter S., Bydon, Mohamad, Freedman, Brett, Sebastian, Arjun S., Lu, Lichun, Kowalchuk, Roman O., Merrell, Kenneth W., Fogelson, Jeremy L., Elder, Benjamin D., Pennington, Zach , Pennington, Zach , Mikula, Anthony L., Lakomkin, Nikita, Clarke, Michelle J., Rose, Peter S., Bydon, Mohamad, Freedman, Brett, Sebastian, Arjun S., Lu, Lichun, Kowalchuk, Roman O., Merrell, Kenneth W., Fogelson, Jeremy L., Elder, Benjamin D.

Mayo Clinic

Journal of Neurosurgery: Spine | April 22, 2022 | Volume: 37 | Issue: 4 | Pages: 617-623

10.3171/2022.2.spine211613 | PMID 35426824 Get It

OBJECTIVE The goal of this study was to determine independent risk factors for vertebral compression fracture (VCF) following radiation for metastatic spine disease, including low bone mineral density as estimated by Hounsfield units (HU). METHODS A retrospective chart review identified patients with a single vertebral column metastasis treated with radiation therapy, a pretreatment CT scan, and a follow-up CT scan at least 6 weeks after treatment. Patients with primary spine tumors, preradiation vertebroplasty, preradiation spine surgery, prior radiation to the treatment field, and proton beam treatment modality were excluded. The HU were measured in the vertebral bodies at the level superior to the metastasis, within the tumor and medullary bone of the metastatic level, and at the level inferior to the metastasis. Variables collected included basic demographics, Spine Instability Neoplastic Score (SINS), presenting symptoms, bone density treatment, primary tumor pathology, Weinstein-Boriani-Biagini (WBB) classification, Enneking stage, radiation treatment details, chemotherapy regimen, and prophylactic vertebroplasty. RESULTS One hundred patients with an average age of 63 years and average follow-up of 18 months with radiation treatment dates ranging from 2017 to 2020 were included. Fifty-nine patients were treated with external-beam radiation therapy, with a median total dose of 20 Gy (range 8–40 Gy). Forty-one patients were treated with stereotactic body radiation therapy, with a median total dose of 24 Gy (range 18–39 Gy). The most common primary pathologies included lung (n = 22), prostate (n = 21), and breast (n = 14). Multivariable logistic regression analysis (area under the curve 0.89) demonstrated pretreatment HU (p < 0.01), SINS (p = 0.02), involvement of ≥ 3 WBB sectors (p < 0.01), primary pathology other than prostate (p = 0.04), and ongoing chemotherapy treatment (p = 0.04) to be independent predictors of postradiation VCF. Patients with pretreatment HU < 145 (n = 32), 145–220 (n = 31), and > 220 (n = 37) had a fracture rate of 59%, 39%, and 11%, respectively. An HU cutoff of 157 was found to maximize sensitivity (71%) and specificity (75%) in predicting postradiation VCF. CONCLUSIONS Low preradiation HU, higher SINS, involvement of ≥ 3 WBB sectors, ongoing chemotherapy, and nonprostate primary pathology were independent predictors of postradiation VCF in patients with metastatic spine disease. Low bone mineral density, as estimated by HU, is a novel and potentially modifiable risk factor for VCF.
Mesenchymal stem cell therapy for focal epilepsy: A systematic review of preclinical models and clinical studies
Perez‐Vega, Carlos , Perkerson, Ralph B., Kanekiyo, Takahisa , Tatum, William O. , Quiñones‐Hinojosa, Alfredo , Middlebrooks, Erik H. , Perez-Vega, Carlos, Lee, Seung-Jin, Takahisa, Kanekiyo, Grewal, Sanjeet , Middlebrooks, Erik H , Ramos‐Fresnedo, Andres , Domingo, Ricardo A. , Lee, Seung Jin , Zubair, Abba C. , Grewal, Sanjeet S.

Mayo Clinic

Epilepsia | April 22, 2022 | Volume: 63 | Issue: 7 | Pages: 1607-1618

10.1111/epi.17266 | PMID 35451066 Get It

AbstractDrug‐resistant epilepsy (DRE) is characterized by recurrent seizures despite appropriate treatment with antiseizure medication (ASM). Due to their regenerative and immunomodulatory potential, therapies with biologics such as mesenchymal stem cells (MSCs) offer a potential therapeutic benefit for structural causes of epilepsy, such as hippocampal sclerosis. In this article, we report a systematic review of the literature evaluating the preclinical and clinical studies of MSCs for DRE. Medline, Ovid EMBASE, Scopus, and the Cochrane Databases were searched electronically from their dates of inception to November 2021 using the following keywords: ((“mesenchymal”) AND (“stem cell”)) AND ((“epilepsy”) OR (“convulsion”) OR (“seizures”)). This review followed Preferred Reporting Items for Systemic Reviews and Meta‐Analyses (PRISMA) guidelines. The initial query identified 488 studies representing 323 unique manuscripts. After application of selection criteria, 15 studies were included in this systematic review; 11 were preclinical studies and 4 were clinical studies. All preclinical studies were performed in rodents and all clinical studies were phase 1 trials. Thus far, therapy with MSCs appears to be safe for use in humans, as no severe adverse events related directly to the therapy were reported. Furthermore, MSC therapy appears to provide a statistically significant clinical benefit by reducing the seizure burden of patients, reducing the electrophysiological biomarkers of epilepsy, and improving their comorbidities, such as depression and anxiety. In addition, animal studies reveal that the therapy exerts its effect by reducing aberrant mossy fiber sprouting (reduce excitatory pathways) and increasing γ‐aminobutyric acid (GABA)ergic interneurons (increase inhibitory pathways). Both preclinical and clinical studies have shown MSC therapy to be safe and preliminary effective, thus warranting further studies to investigate its therapeutic potential.
DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis‐associated variants in the Severe Asthma Research Program
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , Taylor‐Cousar, Jennifer L. , Cutting, Garry R. , Ampleford, E., Hawkins, Gregory A., Zein, Joe , Castro, Mario , Denlinger, Loren C. , Erzurum, Serpil C. , Fahy, John V. , Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Wenzel, Sally E. , Woodruff, Prescott G. , Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Cutting, Gary R , Castro, M , Wenzel, Sally E , Levy, Bruce David , Wenzel, Sally E.

Mayo Clinic

Pediatric Pulmonology | April 22, 2022 | Volume: 57 | Issue: 7 | Pages: 1782-1788

10.1002/ppul.25939 | PMID 35451201 Get It

AbstractBackgroundHeterozygote carriers of potentially pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have increased asthma risk. However, the frequency and impact of CFTR variation among individuals with asthma is unknown.ObjectiveTo determine whether potentially pathogenic CFTR variants associate with disease severity and whether individuals with two potentially pathogenic variants exist in a severe asthma‐enriched cohort.MethodsWe analyzed sequencing data spanning a 190.5Kb region of CFTR in participants from the Severe Asthma Research Program (SARP1‐3). Potentially pathogenic, rare CFTR variants (frequency < 0.05) were classified as CF‐causing or of varying clinical consequences (VVCC) (CFTR2. org). Regression‐based models tested for association between CFTR genotypes (0‐2 potentially pathogenic variants) and severity outcomes.ResultsOf 1401 participants, 9.5% (134) had one potentially pathogenic variant, occurring more frequently in non‐Hispanic white (NHW, 10.1% [84 of 831]) compared to African American individuals (AA, 5.2% [22 of 426]). We found ≥2 potentially pathogenic CFTR variants in 1.4% (19); 0.5% (4) of NHW and 2.8% (12) of AA. Potentially pathogenic CFTR variant genotypes (≥1 or ≥2 variants) were not cumulatively associated with lung function or exacerbations. In NHW, we found three F508del compound heterozygotes with F508del and a VVCC (two 5 T; TG12[c.1210‐11 T > G] and one Arg1070Trp) and a homozygote for the VVCC, 5 T; TG12.ConclusionsWe found potentially pathogenic CFTR variants within a severe asthma‐enriched cohort, including three compound heterozygote genotypes variably associated with CF in NHW individuals. These findings provide the rationale for CFTR sequencing and phenotyping of CF‐related traits in individuals with severe asthma.
Acting to teach communication skills to nurses
Vecchio, Alexis del , Moschella, Phillip , Lanham, Janice Garrison, Zavertnik, Jean Ellen, Del Vecchio, Alexis

Mayo Clinic

The Clinical Teacher | April 22, 2022 | Volume: 19 | Issue: 4 | Pages: 289-293

10.1111/tct.13489 | PMID 35451553 Get It

Abstract Background Interpersonal and communication skills are core competencies for nursing students. Empathetic, patient‐centred communication improves patient outcomes and the care experience. Nursing trainees have reported a lack of preparation and confidence in communication and interpersonal skills with patients and members of the health care team. Acting‐based hands‐on training may provide a novel approach to develop communication in nursing students. Approach The corresponding author worked as a professional actor before pursuing a medical career. He created an acting‐based workshop, inspired by classic acting exercises taught in drama conservatories for decades, to develop core communication and interpersonal skills for health care professionals. The course creator and an instructor with no acting background each facilitated the workshops. The initiative was taught to over 200 preclinical baccalaureate freshmen and sophomore nursing students as part of their clinical skills courses at one institution. Evaluation Participants were asked to rate their self‐efficacy for skills developed in the workshop using a 5‐point Likert scale. A 4 or 5 rating was considered agreement. Most participants agreed the workshop developed their skills of self‐awareness, observation, teamwork, flexibility, nonverbal and verbal communication, trust, mindfulness, body language awareness, active listening, and sensitivity to emotions expressed by others. Implications An acting‐based teaching intervention is efficacious in instilling core communication and interpersonal skills to preclinical nursing students based on participants' self‐efficacy ratings. This innovative way to teaching communication provides students with an experiential environment conducive to learning. Similar ratings between sessions suggest that health professions educators with no formal acting training can successfully teach this course.
Protein‐losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series
Sagray, Ezequiel , Johnson, Jonathan N. , Schumacher, Kurt R. , West, Shawn C. , Lowery, Ray , Simpson, Kathleen E. , West, Shawn , Simpson, Kathleen , Schumacher, K R

Mayo Clinic

Pediatric Transplantation | April 22, 2022 | Volume: 26 | Issue: 5 | Pages: No page available

10.1111/petr.14295 | PMID 35451219 Get It

AbstractBackgroundProtein‐losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.MethodsPatients with Fontan‐related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow‐up were retrospectively identified. Available data related to pre‐ and post‐HTx characteristics and PLE events were collected.ResultsEight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7–21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3–5). PLE recurrences occurred at a median time of 7.5 months after HTx (2–132). Each occurrence was associated with one or more significant clinical events; most commonly cellular‐ or antibody‐mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow‐up at a median time of 4 years (1.3–22.5) after HTx.ConclusionsThis is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.
Endovascular treatments of intracranial vertebral and internal carotid arteries dissections: An interactive systematic review and meta-analysis
Essibayi, Muhammed Amir , Keser, Zafer , Essibayi, Muhammed Amir , Lanzino, Giuseppe , Keser, Zafer

Mayo Clinic

Interventional Neuroradiology | April 22, 2022 | Volume: 30 | Issue: 1 | Pages: 22-30

10.1177/15910199221095789 | PMID 35450460 Get It

Introduction Management of intracranial artery dissection (IAD) remains elusive in medical practice. Intracranially, vertebral artery dissection (VAD) is more commonly encountered than internal carotid artery dissection (ICAD). Deconstructive (EVT-d) and reconstructive (EVT-r) endovascular techniques have been utilized to treat VAD and ICAD. This meta-analysis investigates the safety and efficacy of EVT-r and EVT-d in the management of VAD and ICAD. Methods The literature was searched for all studies with consecutive patient series evaluating EVT-d or EVT-r for VAD or ICAD management. Baseline characteristics and outcomes were compared between EVT-r and EVT-d groups using the random-effect model and meta-regression approaches. Results Overall, 1095 cases pooled from 56 studies were included. There was no statistically significant difference in baseline characteristics between VAD and ICAD. EVT-r was applied in 647 cases (59.1%) and EVT-d in the rest There was no statistical difference in the rate of procedural complications between EVT-r and EVT-d. Although EVT-d was significantly associated with higher rates of complete aneurysm occlusion (86.4%), lower rates of good clinical outcomes (72.1%) and higher mortality (15.1%) were achieved compared to EVT-r (70.2%, 83.3%, and 9.5%; respectively). The mortality rate was higher, and good clinical outcomes were less common in ruptured aneurysms. Ischemic presentation was statistically associated with poor outcomes (mRS 3-5) but low mortality. ICAD often tended to grow following treatment and resulted in poor neurological outcomes. Conclusions IAD has favorable outcomes when treated appropriately. Novel reconstructive endovascular techniques are promising and should be integrated well in endovascular practice. Further studies are warranted.
SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome
Hasselblatt, Martin, Thomas, Christian, Federico, Aniello, Nemes, Karolina, Johann, Pascal D., Bison, Brigitte, Bens, Susanne, Dahlum, Sonja, Kordes, Uwe, Redlich, Antje, Lessel, Lienhard, Pajtler, Kristian W., Mawrin, Christian, Schüller, Ulrich, Nolte, Kay, Kramm, Christof M., Hinz, Felix, Sahm, Felix, Giannini, Caterina, Penkert, Judith, Kratz, Christian P., Pfister, Stefan M., Siebert, Reiner, Paulus, Werner, Kool, Marcel, Frühwald, Michael C., Sahm, Felix , Pfister, Stefan M. , Thomas, Christian , Kordes, Uwe , Redlich, Antje , Pajtler, Kristian W. , Pfister, Stefan M , Pajtler, Kristian W , Sahm, Felix , Thomas, Christian , Hasselblatt, Martin, Thomas, Christian, Federico, Aniello, Nemes, Karolina, Johann, Pascal D., Bison, Brigitte, Bens, Susanne, Dahlum, Sonja, Lessel, Lienhard, Mawrin, Christian, Schüller, Ulrich, Nolte, Kay, Kramm, Christof M., Hinz, Felix, Giannini, Caterina, Penkert, Judith, Kratz, Christian P., Siebert, Reiner, Paulus, Werner, Kool, Marcel, Frühwald, Michael C.

Mayo Clinic

American Journal of Surgical Pathology | April 21, 2022 | Volume: 46 | Issue: 9 | Pages: 1277-1283

10.1097/pas.0000000000001905 | PMID 35446794 Get It

Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant central nervous system tumor predominantly affecting infants. Mutations of SMARCB1 or (rarely) SMARCA4 causing loss of nuclear SMARCB1 or SMARCA4 protein expression are characteristic features, but further recurrent genetic alterations are lacking. Most AT/RTs occur de novo, but secondary AT/RTs arising from other central nervous system tumors have been reported. Malignant gliomas, IDH wild-type, arising in patients with Li-Fraumeni syndrome typically show somatic mutations of TP53 as well as complex copy number alterations, but little is known about the loss of SMARCB1 or SMARCA4 protein expression in this context. Here, we report 2 children in whom malignant supratentorial brain tumors with SMARCB1 deficiency, complex copy number alterations, and somatic TP53 mutations lead to the discovery of pathogenic/likely pathogenic TP53 variants in the germline. Screening of the molecularneuropathology.org dataset for cases with similar genetic and epigenetic alterations yielded another case with SMARCA4 deficiency in a young adult with Li-Fraumeni syndrome. In conclusion, SMARCB1-deficient or SMARCA4-deficient malignant brain tumors with complex copy number alterations and somatic TP53 mutations in children and young adults may represent the first clinical manifestation of Li-Fraumeni syndrome and should prompt genetic counseling and investigation for TP53 germline status.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
Agarwal, Neeraj , Tangen, Catherine M. , Hussain, Maha , Gupta, Shilpa , Plets, Melissa , Lara, Primo N. , Harzstark, Andrea, Twardowski, Przemyslaw, Paller, Channing J. , Zylla, Dylan M. , Zibelman, Matthew R. , Levine, Ellis , Roth, Bruce J. , Goldkorn, Amir , Vaena, Daniel A. , Crispino, Tony, Thompson, Ian M. , Hussain, Maha H A , Zylla, Dylan , Kohli, Manish , Vogelzang, Nicholas J , Quinn, David I , Agarwal, Archana M , Paller, Channing J , Tangen, Catherine M , Thompson, Ian M , Kohli, Manish , Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | April 21, 2022 | Volume: 40 | Issue: 28 | Pages: 3301-3309

10.1200/jco.21.02517 | PMID 35446628 Get It

PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. METHODS In this open-label randomized phase III study, patients with metastatic hormone-sensitive prostate cancer were randomly assigned 1:1 to ADT with orteronel (300 mg oral twice daily; experimental arm) or ADT with bicalutamide (50 mg oral once daily; control arm). The primary objective was the comparison of overall survival (OS), targeting a 33% improvement in median survival. A stratified log-rank test with a one-sided P ≤ .022 would indicate statistical significance. Secondary end points were progression-free survival (PFS), prostate-specific antigen (PSA) level at 7 months (≤ 0.2 v 0.2 to ≤ 4 v > 4 ng/mL), and adverse event profile. RESULTS Among 1,279 patients included in the analysis, 638 were randomly assigned to the ADT plus orteronel arm and 641 to the control arm. The median age was 68 years; 49% had extensive disease. After a median follow-up of 4.9 years, there was a significant improvement in PFS (median 47.6 v 23.0 months, hazard ratio 0.58; 95% CI, 0.51 to 0.67; P < .0001) and PSA response at 7 months ( P < .0001), but not in OS (median 81.1 v 70.2 months, hazard ratio 0.86; 95% CI, 0.72 to 1.02; P = .040, one-sided). More grade 3/4 adverse events occurred in the experimental versus the control arms (43% v 14%). Postprotocol life-prolonging therapy was received by 77.4% of patients in the control arm and 61.3% of patients in the orteronel arm. CONCLUSION The study did not meet the primary end point of improved OS with orteronel. The lack of correlation of PFS and PSA response with OS raises concerns over assumption of their consistent surrogacy for OS in the context of extensive postprotocol therapy in this setting.